The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?
 
Jose Mauricio S. C. Mota
No Relationships to Disclose
 
Min Yuen Teo
Research Funding - Bristol-Myers Squibb
 
Han Li
No Relationships to Disclose
 
Arjun Vasant Balar
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Incyte; Merck; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Matthew I. Milowsky
Consulting or Advisory Role - BioClin Therapeutics
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Second Science; Urogen pharma (I)
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Chung-Han Lee
Consulting or Advisory Role - Eisai; Eisai; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - Roche
Research Funding - Illumina
 
David B. Solit
Consulting or Advisory Role - Illumina; Intezyne Technologies; Loxo; Pfizer; Vividion Therapeutics
Travel, Accommodations, Expenses - Merck KGaA
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; Inovio Pharmaceuticals; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Sanofi; Seagen; Sensei Biotherapeutics
Research Funding - Agensys (Inst); Bayer (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Gopa Iyer
Consulting or Advisory Role - Bayer